Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for Allogene Therapeutics (ALLO) over the last 5 years, with Dec 2024 value amounting to $20.2 million.

  • Allogene Therapeutics' Interest & Investment Income fell 41.45% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 20.24%. This contributed to the annual value of $20.2 million for FY2024, which is 10.08% up from last year.
  • Allogene Therapeutics' Interest & Investment Income amounted to $20.2 million in FY2024, which was up 10.08% from $18.3 million recorded in FY2023.
  • Allogene Therapeutics' Interest & Investment Income's 5-year high stood at $20.2 million during FY2024, with a 5-year trough of $1.7 million in FY2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $18.3 million (2023), whereas its average is $14.3 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 81.30% in 2021, then spiked by 300.94% in 2023.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Interest & Investment Income stood at $9.2 million in 2020, then tumbled by 81.30% to $1.7 million in 2021, then skyrocketed by 166.39% to $4.6 million in 2022, then surged by 300.94% to $18.3 million in 2023, then grew by 10.08% to $20.2 million in 2024.